capivasertib plus paclitaxel 3 studies la/mBC - HR-positive - 1st line (L1) mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population
ipatasertib plus paclitaxel 2 studies la/mBC - HR positive - L1 - PIK3CA mutant mBC - TNBC - L1 - all population
enfortumab vedotin-ejfv 1 studies urothelial cancer (UC) - bladder cancer (BC)
sacituzumab govitecan 4 studies urothelial cancer (UC) - bladder cancer (BC) mBC-Triple negative (TNBC) - 2nd Line (L2)
tisotumab vedotin-tftv 1 studies cervical cancer (CC)
trastuzumab deruxtecan 4 studies gastric or gastroesophageal junction cancer (GC) lung cancer : non small cell (NSCLC) metastatic/advanced - breast cancer (mBC) la/mBC - HER2 positive - 2nd Line (L2)
trastuzumab emtansine 7 studies es-BC - HER2 positive - (neo)adjuvant (NA) es-BC - HR positive - (neo)adjuvant (NA) breast cancer - adjuvant la/mBC - HER2 positive - 2nd Line (L2)
trastuzumab emtasine plus endocrine therapy 3 studies breast cancer - adjuvant es-BC - HER2 positive - (neo)adjuvant (NA) es-BC - HR positive - (neo)adjuvant (NA)
alisertib plus paclitaxel 1 studies la/mBC - HR-positive - 2nd line (L2)
metformin 1 studies la/mBC - HR-positive - 2nd line (L2)
mirvetuximab soravtansine-gynx 1 studies ovarian cancer (OC)
teclistamab-cqyv 1 studies multiple myeloma
celecoxib plus endocrine therapy 1 studies la/mBC - HR-positive - 2nd line (L2)
pralatrexate 1 studies mNSCLC - L2 - all population
non platinum-based chemotherapy
lurbinectedin 1 studies lung cancer : small cell (SCLC)
rituximab alone 43 studies neutropenia
abemaciclib plus aromatase inhibitor 1 studies la/mBC - HR-positive - 1st line (L1)
abemaciclib plus BSC 1 studies mNSCLC - L2 - KRAS mutant
abemaciclib plus endocrine therapy 2 studies la/mBC - HR-positive - 1st line (L1) breast cancer - adjuvant
abemaciclib plus fulvestrant 1 studies la/mBC - HR-positive - 2nd line (L2)
abemaciclib plus trastuzumab 1 studies la/mBC - HER2 positive - 2nd Line (L2)
abemaciclib plus trastuzumab plus fulvestrant 1 studies la/mBC - HER2 positive - 2nd Line (L2)
dalpiciclib plus fulvestrant 1 studies la/mBC - HR-positive - 2nd line (L2)
palbociclib 1 studies breast cancer - adjuvant
palbociclib plus endocrine therapy 3 studies la/mBC - HR positive la/mBC - HR-positive - 1st line (L1) breast cancer - adjuvant
palbociclib plus fulvestrant 3 studies la/mBC - HR-positive - 2nd line (L2)
palbociclib plus letrozole 2 studies la/mBC - HR-positive - 1st line (L1)
ribociclib plus endocrine therapy 1 studies la/mBC - HR-positive - 2nd line (L2)
ribociclib plus fulvestrant 1 studies la/mBC - HR-positive - 2nd line (L2)
ribociclib plus letrozole 1 studies la/mBC - HR-positive - 1st line (L1)
androgen deprivation therapy (ADT)
abiraterone plus ADT 2 studies metastatic, hormone-sensitive prostate cancer
abiraterone plus docetaxel plus ADT 1 studies metastatic, hormone-sensitive prostate cancer
apalutamide plus ADT 1 studies metastatic, hormone-sensitive prostate cancer
darolutamide plus doxetaxel plus ADT 1 studies metastatic, hormone-sensitive prostate cancer
docetaxel plus ADT 4 studies metastatic, hormone-sensitive prostate cancer
enzalutamide plus ADT 2 studies metastatic, hormone-sensitive prostate cancer
orteronel 1 studies metastatic, hormone-sensitive prostate cancer
gene alteration target therapy
alectinib 2 studies lung cancer : non small cell (NSCLC)
brigatinib 1 studies lung cancer : non small cell (NSCLC)
ceritinib 1 studies lung cancer : non small cell (NSCLC)
crizotinib 3 studies myofibroblastic tumors lung cancer : non small cell (NSCLC)
BRAF gene alteration targeted therapy
encorafenib plus binimetinib 2 studies colorectal cancer (CRC) melanoma (ML)
amivantamab-vmjw 5 studies lung cancer : non small cell (NSCLC) EGFR exon 20 insertion mutation EGFR gene alteration defined cancer
mobocertinib 2 studies lung cancer : non small cell (NSCLC) EGFR exon 20 insertion mutation
osimertinib 6 studies eNSCLC - NA - EGFR mutant mNSCLC - L2 - EGFR mutant mNSCLC - L1 - all population
FGFR (2/3) gene alteration targeted therapy
erdafitinib 3 studies urothelial cancer (UC) - bladder cancer (BC) FGFR (2/3) gene alteration defined cancer
futibatinib 1 studies cholangiocarcinoma
infigratinib 3 studies biliary tract cancer (BTC) cholangiocarcinoma FGFR (2/3) gene alteration defined cancer
pemigatinib 1 studies cholangiocarcinoma
KRAS gene alteration targeted therapy
adagrasib 1 studies lung cancer : non small cell (NSCLC)
sotorasib 6 studies metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) lung cancer : non small cell (NSCLC) KRAS gene alteration defined cancer
MET gene alteration targeted therapy
capmatinib 2 studies lung cancer : non small cell (NSCLC)
savolitinib 1 studies lung cancer : non small cell (NSCLC)
tepotinib 2 studies lung cancer : non small cell (NSCLC)
NTRK gene alteration targeted therapy
entrectinib 1 studies lung cancer : non small cell (NSCLC)
larotrectinib 5 studies lung cancer : non small cell (NSCLC) NTRK gene alteration
RET gene alteration targeted therapy
pralsetinib 3 studies lung cancer : non small cell (NSCLC) RET gene alteration defined cancer
retifanlimab-dlwr 1 studies A EFFACER all cancer
selpercatinib 6 studies lung cancer : non small cell (NSCLC) RET gene alteration defined cancer thyroid cancer
repotrectinib 1 studies lung cancer : non small cell (NSCLC)
selumetinib 1 studies neurofibroma
entinostat plus exemestane 2 studies la/mBC - HR-positive - 2nd line (L2)
tucidinostat plus exemestane 1 studies la/mBC - HR-positive - 2nd line (L2)
afatinib alone 4 studies mNSCLC - L1 - EGFR mutant non squamous - mNSCLC - L2 - all population
afatinib plus BSC 1 studies mNSCLC - L2 - all population
afatinib plus paclitaxel 1 studies mNSCLC - L2 - all population
afatinib plus vinorelbine 1 studies la/mBC - HER2 positive - 2nd Line (L2)
dacomitinib 6 studies mNSCLC - L2 - KRAS wild type mNSCLC - L2 - all population mNSCLC - L1 - EGFR mutant EGFR gene alteration defined cancer
erlotinib alone 25 studies mNSCLC - L1 - all population mNSCLC - L2 - EGFR wild type mNSCLC - L1 - EGFR mutant laNSCLC - NA - all population mNSCLC - M - EGFR wild type metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population mNSCLC - NA - all population mNSCLC - M - all population early NSCLC - (neo)adjuvant (NA)
erlotinib followed by gemcitabine plus platin 1 studies mNSCLC - M - all population
erlotinib plus bevacizumab 3 studies non squamous - mNSCLC - L1 - all population mNSCLC - M - EGFR mutant
erlotinib plus cisplatin and gemcitabine 2 studies mNSCLC - L1 - all population
erlotinib plus gemcitabine 1 studies mNSCLC - L2 - all population
erlotinib plus pemetrexed 2 studies mNSCLC - L2 - all population non squamous - mNSCLC - L1 - all population
erlotinib plus SoC 3 studies mNSCLC - NA - all population metastatic/adv NSCLC (mNSCLC) - maintenance (M) mNSCLC - L1 - all population
tivantinib plus erlotinib 1 studies mNSCLC - L2 - KRAS mutant
gefitinib alone 20 studies metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population mNSCLC - NA - all population non squamous - mNSCLC - L2 - wild type (WT) eNSCLC - NA - EGFR mutant mNSCLC - L1 - all population mNSCLC - L2 - EGFR high mNSCLC - M - all population mNSCLC - L1 - EGFR mutant laNSCLC - NA - all population
gefitinib plus BSC 2 studies mNSCLC - L1 - all population mNSCLC - L2 - all population
gefitinib plus pemetrexed plus platin 2 studies metastatic/adv NSCLC (mNSCLC) - maintenance (M)
gefitinib plus SoC (rechallenge) 1 studies mNSCLC - L2 - EGFR mutant
pemetrexed plus platin followed by maintenance gefitinib 1 studies non squamous - mNSCLC - L1 - all population
SoC followed by gefitinib 1 studies mNSCLC - L1 - all population
icotinib 1 studies mNSCLC - L2 - all population
naquotinib 1 studies mNSCLC - L1 - EGFR mutant
nimotuzumab plus gefitinib 1 studies mNSCLC - L2 - all population
neratinib 2 studies la/mBC - HER2 positive - 2nd Line (L2) breast cancer - adjuvant
neratinib plus capecitabine 2 studies la/mBC - HER2 positive - 2nd Line (L2)
pertuzumab plus trastuzumab 3 studies la/mBC - HER2 positive - 1st Line (L1) breast cancer - adjuvant
pertuzumab plus trastuzumab plus docetaxel 2 studies la/mBC - HER2 positive - 1st Line (L1)
docetaxel plus carboplatin with trastuzumab followed by trastuzumab 1 studies breast cancer - adjuvant
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab 2 studies breast cancer - adjuvant
trastuzumab 1 studies la/mBC - HER2 positive - 1st Line (L1)
trastuzumab followed by lapatinib 1 studies la/mBC - HER2 positive
trastuzumab plus chemotherapy 1 studies la/mBC - HER2 positive - (neo)adjuvant (NA)
trastuzumab plus endocrine therapy 2 studies la/mBC - HER2 positive - 1st Line (L1) la/mBC - HR-positive - 1st line (L1)
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel 1 studies es-BC - HER2 positive - (neo)adjuvant (NA)
tucatinib plus trastuzumab plus capecitabine 2 studies la/mBC - HER2 positive - 2nd Line (L2)
TKI anti HER1/EGFR and HER2/neu
lapatinib 4 studies la/mBC - HER2 positive es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - adjuvant la/mBC - HER2 positive - 2nd Line (L2)
lapatinib plus capecitabine 2 studies la/mBC - HER2 positive - 2nd Line (L2)
lapatinib plus fulvestrant 1 studies la/mBC - HR-positive - 1st line (L1)
lapatinib plus letrozole 2 studies la/mBC - HR-positive - 1st line (L1)
lapatinib plus paclitaxel 1 studies la/mBC - HER2 positive - (neo)adjuvant (NA)
lapatinib plus trastuzumab 2 studies la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
lapatinib plus trastuzumab plus paclitaxel 1 studies la/mBC - HER2 positive - (neo)adjuvant (NA)
HIF-2α inhibitor 1 studies renal cell cancer (RCC)
dalotuzumab plus ridaforolimus plus exemestane 1 studies la/mBC - HR-positive - 1st line (L1)
ganitumab plus endocrine therapy 1 studies la/mBC - HR-positive - 2nd line (L2)
Ipilimumab (10 mg/kg) 5 studies mML - NA - all population mGC or mGEJC - L2 - all population mML - L2 - all population
ipilimumab plus gp100 2 studies mML - L2 - all population
ipilimumab plus SoC 4 studies Extensive stage SCLC (Es-SCLC) - 1st Line (L1) squamous - mNSCLC - L1 - all population mML - L2 - all population
tremelimumab 2 studies malignant mesothelioma (mMS) - 2nd line (L2) mML - L1 - all population
atezolizumab alone 20 studies lung cancer : non small cell (NSCLC) mNSCLC - L1 - PDL1 positive mNSCLC - L2 - PDL1 positive mUC - L2 - all population mUC - L2 - PDL1 positive mUC - L1 - all population mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mCRC - 2nd line (L2) early NSCLC - 1st line (L1) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) MIBC - NA - all population mNSCLC - L2 - all population
atezolizumab plus bevacizumab 6 studies mRCC - L1 - PDL1 positive mRCC - L1 - PDL1 negative mHCC - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel 3 studies non squamous - mNSCLC - L1 - all population non squamous - mNSCLC - L1 - Wild Type (WT)
atezolizumab plus carboplatin plus nab-paclitaxel 4 studies non squamous - mNSCLC - L1 - all population es-BC - TNBC - NA - all population non squamous - mNSCLC - L1 - Wild Type (WT) squamous - mNSCLC - L1 - all population
atezolizumab plus carboplatin plus paclitaxel 2 studies squamous - mNSCLC - L1 - all population non squamous - mNSCLC - L1 - all population
atezolizumab plus cometinib 2 studies mML - L1 - BRAF wild mCRC - 2nd line (L2)
atezolizumab plus nab-paclitaxel 2 studies mBC - TNBC - L1 - PDL1 positive mBC - TNBC - L1 - all population
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 2 studies es-BC - TNBC - NA - PDL1 positive es-BC - TNBC - NA - all population
atezolizumab plus paclitaxel 2 studies mBC - TNBC - L1 - PDL1 positive mBC - TNBC - L1 - all population
atezolizumab plus pemetrexed and platin 1 studies non squamous - mNSCLC - L1 - Wild Type (WT)
atezolizumab plus SoC 5 studies mOC - L1 - PDL1 positive mML - L1 - BRAF mutant mOC - L1 - all population Extensive stage SCLC (Es-SCLC) - 1st Line (L1) mUC - L1 - all population
avelumab alone 10 studies urothelial cancer (UC) - bladder cancer (BC) mGC or mGEJC - M - HER2 neg/PDL1 positive mNSCLC - L2 - all population mUC - M - PDL1 positive metastatic/advanced OC (mOC) - 2nd line (L2) laHNSCC - 1st line (L1) mNSCLC - L2 - PDL1 positive mGC or mGEJC - L2 - all population mGC or mGEJC - M - HER2 negative mUC - M - all population
avelumab plus axitinib 2 studies metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
avelumab plus pegylated liposomal doxorubicin 1 studies metastatic/advanced OC (mOC) - 2nd line (L2)
avelumab plus SoC 1 studies metastatic/advanced OC (mOC) - maintenance (M)
camrelizumab alone 1 studies mEC - 2nd line (L2)
cemiplimab 3 studies basal cell carcinoma mNSCLC - L1 - PDL1 positive mNSCLC - L1 - all population
dostarlimab 1 studies colorectal cancer (CRC)
durvalumab plus osimertinib 1 studies mNSCLC - L2 - EGFR mutant
durvalumab plus etoposide and platin 1 studies Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
durvalumab plus SoC 1 studies early NSCLC - (neo)adjuvant (NA)
nivolumab plus cabozantinib 1 studies metastatic/advanced RCC (mRCC) - 1st line (L1)
nivolumab plus SoC 7 studies NSCLC neoadjuvant setting mGC or mGEJC - L1 - HER2 neg/PDL1 positive mNSCLC - L1 - PDL1 negative mGC or mGEJC - L1 - HER2 negative locally advanced NSCLC - (neo)adjuvant (NA)
nivolumab followed by ipilimumab 1 studies mML - L1 - all population
pembrolizumab (10mg/kg) 4 studies mNSCLC - L2 - PDL1 positive mML - L2 - all population
pembrolizumab (10mg/kg) 2 weeks 1 studies mML - L2 - all population
pembrolizumab (2mg/kg) 3 studies mNSCLC - L2 - PDL1 positive mML - L2 - all population
pembrolizumab and pemetrexed plus platin 1 studies non squamous - mNSCLC - L1 - Wild Type (WT)
pembrolizumab plus 5FU plus platin 3 studies mHNSCC - L1 - PDL1 positive mHNSCC - L1 - all population
pembrolizumab plus axitinib 1 studies metastatic/advanced RCC (mRCC) - 1st line (L1)
pembrolizumab plus lenalidomide and dexamethasone 1 studies multiple myeloma - 1st line (L1)
pembrolizumab plus lenvatinib 4 studies mHCC - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1) endometrial cancer
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide 1 studies es-BC - HER2 negative - (neo)adjuvant (NA)
pembrolizumab plus pomalidomide and dexamethasone 1 studies multiple myeloma - 2nd line (L2)
pembrolizumab plus SoC 14 studies locally advanced NSCLC - (neo)adjuvant (NA) NSCLC neoadjuvant setting mBC - TNBC - L1 - PDL1 positive mBC - TNBC - L1 - all population glioblastoma (GB) mGC or mGEJC - L1 - PDL1 positive mEC - 1st line (L1) mML - L2 - BRAF mutant Extensive stage SCLC (Es-SCLC) - 1st Line (L1) mUC - L1 - all population non squamous - mNSCLC - L1 - Wild Type (WT) squamous - mNSCLC - L1 - all population
sintilimab 1 studies mHCC - 1st line (L1)
sintillimab plus SoC 1 studies mNSCLC - L1 - all population
Tislelizumab 1 studies mNSCLC - L2 - all population
tiragolumab 3 studies lung cancer : non small cell (NSCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
durvalumab plus tremelimumab plus SoC 1 studies Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
nivolumab plus ipilimumab plus SoC 1 studies mNSCLC - L1 - all population
pembrolizumab plus ipilimumab 1 studies mNSCLC - L1 - PDL1 positive
relatlimab plus nivolumab 1 studies mML - L1 - all population
IRX-2 1 studies head and neck cancer squamous cell cancer (HNSCC)
AE37 vaccine plus GM-CSF 1 studies breast cancer (BC)
GP2 vaccine plus GM-CSF 1 studies breast cancer (BC)
OBI-822/OBI-821 plus cyclophosphamide 1 studies la/mBC - HR-positive - 2nd line (L2)
inetetamab plus vinorelbine 1 studies la/mBC - HER2 positive - 2nd Line (L2)
lenvatinib plus everolimus 1 studies metastatic/advanced RCC (mRCC) - 1st line (L1)
sapanisertib plus fulvestrant 2 studies la/mBC - HR-positive - 2nd line (L2)
phosphoinositide 3-kinase (PI3K) inhibitor
alpelisib 1 studies PIK3CA-related overgrowth spectrum
alpelisib plus fulvestrant 2 studies la/mBC - HR-positive - 2nd line (L2)
alpelisib plus letrozole 2 studies la/mBC - HR positive - (neo)adjuvant (NA)
buparlisib plus fulvestrant 4 studies la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive la/mBC - HR positive - L2 - PIK3CA mutant la/mBC - HR positive - L2 - all population
buparlisib plus letrozole 1 studies la/mBC - HR positive - (neo)adjuvant (NA)
taselisib plus letrozole 1 studies es-BC - HR-positive - 1st line (L1)
poly ADP-ribose polymerase (PARP) inhibitor
niraparib 2 studies prostate cancer (PC) ovarian cancer (OC)
olaparib 13 studies ovarian cancer (OC) BRCA1/2 gene alteration defined cancer prostate cancer (PC) urothelial cancer (UC) - bladder cancer (BC) es-BC - TNBC - NA - all population breast cancer - adjuvant mBC - TNBC - L2 - all population
rucaparib 7 studies prostate cancer (PC) BRCA1/2 gene alteration defined cancer ovarian cancer (OC)
talazoparib 1 studies mBC-Triple negative (TNBC) - 2nd Line (L2)
veliparib plus paclitaxel plus carboplatin 2 studies mBC - TNBC - L1 - all population
margetuximab plus chemotherapy 1 studies la/mBC - HER2 positive - 2nd Line (L2)
nintedanib 1 studies ovarian cancer (OC)
bevacizumab 1 studies ovarian cancer (OC)
bevacizumab plus trastuzumab plus docetaxel 1 studies la/mBC - HER2 positive - 1st Line (L1)
cediranib plus fulvestrant 1 studies la/mBC - HR-positive - 1st line (L1)
lenvatinib in association 3 studies metastatic/advanced RCC (mRCC) - 1st line (L1) endometrial cancer
ramucirumab plus erlotinib 1 studies mNSCLC - L1 - EGFR mutant
sorafenib and erlotinib 1 studies mNSCLC - L1 - all population
vandetanib 2 studies mNSCLC - L2 - all population